"Designing Growth Strategies is in our DNA"
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1 Prevalence of glioma by key countries
4.2 Overview of technological advancements in the glioma therapy
4.3 Recent industry developments such as mergers& acquisitions
4.4 Pipeline Analysis
5. Global Adult Malignant Glioma Therapeutics Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Application
5.2.1 Glioblastoma Multiforme
5.2.2 Anaplastic Astrocytoma
5.2.3 Anaplastic Oligodendroglioma
5.2.4 Others
5.3 Market Analysis, Insights and Forecast – By Type
5.3.1 Chemotherapy
5.3.2 Radiotherapy
5.3.3 Targeted Therapy
5.3.4 Others
5.4. Market Analysis, Insights and Forecast – By End User
5.4.1 Hospitals
5.4.2 Specialty Clinics
5.4.3 Cancer and Radiation Therapy Centers
5.4.4 Others
5.5. Market Analysis, Insights and Forecast – By Country
5.5.1 North America
5.5.2 Europe
5.5.3 Asia Pacific
5.5.4 Rest of World
6. North America Adult Malignant Glioma Therapeutics Market Analysis, Insights andForecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis – By Application
6.2.1 Glioblastoma Multiforme
6.2.2 Anaplastic Astrocytoma
6.2.3 Anaplastic Oligodendroglioma
6.2.4 Others
6.3. Market Analysis – By Type
6.3.1 Chemotherapy
6.3.2 Radiotherapy
6.3.3 Targeted Therapy
6.3.4 Others
6.4. Market Analysis – By End User
6.4.1 Hospitals
6.4.2 Specialty Clinics
6.4.3 Cancer and Radiation Therapy Centers
6.4.4 Others
6.5. Market Analysis – By Country
6.5.1 U.S
6.5.2 Canada
7. Europe Adult Malignant Glioma Therapeutics Market Analysis, Insights and Forecast,2015-2026
7.1. Key Findings / Summary
7.2. Market Analysis – By Application
7.2.1 Glioblastoma Multiforme
7.2.2 Anaplastic Astrocytoma
7.2.3 Anaplastic Oligodendroglioma
7.2.4 Others
7.3. Market Analysis – By Type
7.3.1 Chemotherapy
7.3.2 Radiotherapy
7.3.3 Targeted Therapy
7.3.4 Others
7.4. Market Analysis – By End User
7.4.1 Hospitals
7.4.2 Specialty Clinics
7.4.3 Cancer and Radiation Therapy Centers
7.4.4 Others
7.5. Market Analysis – By Country
7.5.1 Germany
7.5.2 U.K.
7.5.3 France
7.5.4 Italy
7.5.5 Spain
7.5.6 Scandinavia
7.5.7 Rest of Europe
8. Asia Pacific Adult Malignant Glioma Therapeutics Market Analysis, Insights andForecast, 2015-2026
8.1. Key Findings / Summary
8.2. Market Analysis – By Application
8.2.1 Glioblastoma Multiforme
8.2.2 Anaplastic Astrocytoma
8.2.3 Anaplastic Oligodendroglioma
8.2.4 Others
8.3. Market Analysis – By Type
8.3.1 Chemotherapy
8.3.2 Radiotherapy
8.3.3 Targeted Therapy
8.3.4 Others
8.4. Market Analysis – By End User
8.4.1 Hospitals
8.4.2 Specialty Clinics
8.4.3 Cancer and Radiation Therapy Centers
8.4.4 Others
8.5. Market Analysis – By Country
8.5.1 India
8.5.2 China
8.5.3 Japan
8.5.4 Australia
8.5.5 Southeast Asia
8.5.6 Rest of Asia Pacific
9. Rest of World Adult Malignant Glioma Therapeutics Market Analysis, Insights andForecast, 2015-2026
9.1. Key Findings / Summary
9.2. Market Analysis – By Application
9.2.1 Glioblastoma Multiforme
9.2.2 Anaplastic Astrocytoma
9.2.3 Anaplastic Oligodendroglioma
9.2.4 Others
9.3. Market Analysis – By Type
9.3.1 Chemotherapy
9.3.2 Radiotherapy
9.3.3 Targeted Therapy
9.3.4 Others
9.4. Market Analysis – By End User
9.4.1 Hospitals
9.4.2 Specialty Clinics
9.4.3 Cancer and Radiation Therapy Centers
9.4.4 Others
10. Competitive Analysis
10.1. Key Industry Developments
10.2. Global Market Share Analysis (2018)
10.3. Competition Dashboard
10.4. Comparative Analysis – Major Players
10.5. Company Profiles (Overview, Products &services, SWOT analysis, Recent developments, strategies, financials (based onavailability))
10.5.1 Merck& Co., Inc.
10.5.2 F.Hoffmann-La Roche Ltd
10.5.3 ArborPharmaceuticals
10.5.4 PfizerInc.
10.5.5 AbbVieInc.
10.5.6 AmgenInc.
10.5.7 Bristol-Myers Squibb Company
10.5.8 Sun Pharmaceutical Industries Ltd.
10.5.9 Teva Pharmaceutical Industries Ltd.
11. Strategic Recommendations
Related Reports